Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
31
REVB Quote, Financials, Valuation and Earnings
Last price:
$1.05
Seasonality move
:
-45.69%
Day range:
$1.00 - $1.09
52-week range:
$0.83 - $60.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.56x
Volume:
84.5K
Avg. volume:
111.9K
1-year change:
-95.25%
Market cap:
$6.1M
Revenue:
--
EPS (TTM):
-$25.83
Analysts' Opinion
-
Consensus RatingRevelation Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.25, Revelation Biosciences, Inc. has an estimated upside of 1953.14% from its current price of $1.04.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $1.04.
Fair Value
-
According to the consensus of 1 analyst, Revelation Biosciences, Inc. has 1953.14% upside to fair value with a price target of $21.25 per share.
REVB vs. S&P 500
-
Over the past 5 trading days, Revelation Biosciences, Inc. has overperformed the S&P 500 by 8.09% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Revelation Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Revelation Biosciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Revelation Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Revelation Biosciences, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Revelation Biosciences, Inc. reported earnings per share of -$1.77.
Enterprise value:
-6.6M
EV / Invested capital:
-0.60x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$28.4K
Return On Assets:
-114.22%
Net Income Margin (TTM):
--
Return On Equity:
-161.98%
Return On Invested Capital:
-161.98%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$25K | -$27K | -$28.4K | -$7.2K | -$6.8K | |
| Operating Income | -$7.5M | -$8.5M | -$8.3M | -$1.8M | -$1.9M | |
| EBITDA | -$7.5M | -$8.5M | -$8.2M | -$1.8M | -$1.9M | |
| Diluted EPS | -$14.12 | -$16.75 | -$25.83 | -$0.84 | -$1.77 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $39.1K | $6.5M | $14.1M | $6.7M | $12.8M | |
| Total Assets | $73.6M | $6.6M | $14.2M | $6.7M | $12.9M | |
| Current Liabilities | $3.7M | $4.4M | $5.4M | $4.1M | $1.9M | |
| Total Liabilities | $6.6M | $4.4M | $5.4M | $4.1M | $1.9M | |
| Total Equity | $66.9M | $2.2M | $8.8M | $2.7M | $11M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.2M | -$16.6M | -$10.1M | -$9.3M | -$1.6M | |
| Cash From Investing | -- | -$36.9K | $17.7K | -$17.7K | -- | |
| Cash From Financing | $14M | $9.2M | $16.2M | $3.7M | $9.1M | |
| Free Cash Flow | -$6.2M | -$16.6M | -$10M | -$9.3M | -$1.6M | |
REVB
Sector
Market Cap
$6.1M
$28.5M
Price % of 52-Week High
1.71%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-318.14%
-1.33%
1-Year Price Total Return
-95.25%
-20.32%
Beta (5-Year)
-0.104
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.95
200-day SMA
Sell
Level
$4.40
Bollinger Bands (100)
Sell
Level
1.06 - 2.54
Chaikin Money Flow
Sell
Level
-25.7M
20-day SMA
Buy
Level
$0.93
Relative Strength Index (RSI14)
Buy
Level
51.14
ADX Line
Buy
Level
20.75
Williams %R
Neutral
Level
-21.162
50-day SMA
Sell
Level
$1.17
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
25.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.487)
Sell
CA Score
(Annual)
Level (-3.811)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (18.0717)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, REVB has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The REVB average analyst price target in the past 3 months is $21.25.
-
Where Will Revelation Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Revelation Biosciences, Inc. share price will rise to $21.25 per share over the next 12 months.
-
What Do Analysts Say About Revelation Biosciences, Inc.?
Analysts are divided on their view about Revelation Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Revelation Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Revelation Biosciences, Inc.'s Price Target?
The price target for Revelation Biosciences, Inc. over the next 1-year time period is forecast to be $21.25 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is REVB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Revelation Biosciences, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of REVB?
You can purchase shares of Revelation Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Revelation Biosciences, Inc. shares.
-
What Is The Revelation Biosciences, Inc. Share Price Today?
Revelation Biosciences, Inc. was last trading at $1.05 per share. This represents the most recent stock quote for Revelation Biosciences, Inc.. Yesterday, Revelation Biosciences, Inc. closed at $1.04 per share.
-
How To Buy Revelation Biosciences, Inc. Stock Online?
In order to purchase Revelation Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get REVB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
REVB
Sector
P/E ratio
--
23.75x
PEG ratio
0.00x
-0.01x
P/B ratio
0.56x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
REVB
Sector
Revenue growth
--
4.85%
Earnings growth
-111.43%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$1.34
-$0.20
Profitability
REVB
Sector
Profitability FY 2024
-$27.9K
$3.6M
Return on invested capital
-161.98%
-30.98%
Return on assets
-114.22%
-27.62%
Return on equity
-161.98%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
REVB
Sector
Total cash
$12.7M
$27.2M
Short term investments
--
$25.7M
Total assets
$6.6M
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
72
KYMR alert for Dec 8
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
